EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...
EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) todayMaximize Your Portfolio with Data Driven ...
Explore Cathie Wood's latest investment insights on the convergence of artificial intelligence in shaping the future, as ...
Cathie Wood stocks have done well in the past few months, with the ARK Innovation ETF (ARKK) soaring by 72% to $64. It has ...
Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.
Legendary fund manager Cathie Wood isn’t typically associated with boring, dividend-paying companies. Known for picking up ...
24/7 Wall St. on MSN18h
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last YearLow-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years. However, with much of the outsized gains coming from just a handful of names (at the ...
Chinese technology stocks are witnessing a surge, spearheaded by DeepSeek, thereby closing the valuation gap with the U.S. 'Magnificent Seven'.
Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback